Hypera Pharma is Brazil’s largest pharmaceutical company in net sales. It’s present in all relevant segments of the retail pharmaceutical sector in Brazil, with leadership in several product categories. The company offers high-quality products, and keeps investing in innovation to grow in a sustainable way.
Hypera Pharma is organized into five major business units:
With the umbrella brand Mantecorp Farmasa, the Company operates in several medical specialties in Primary Care, with brands such as Predsim, Celestamine, Maxsulid, Nesina, Diprospan, Colflex and Addera D3.
With Mantecorp Skincare, it offers dermocosmetics recommended by dermatologists all over Brazil, according to information from Close-up International. It also acts in this segment with the brands Simple Organic, of organic, vegan and cruelty-free products, and Bioage, focused on the market of professional aesthetic treatments.
The Company is the leader in the Brazilian OTC market with approximately 20% market share, according to IQVIA data, with brands such as Apracur, Benegrip, Buscopan, Coristina d, Engov, Epocler, Estomazil and Neosaldina. It also operates in the nutritional, sweeteners and vitamin supplement lines, with brands such as Tamarine, Vitasay 50+, Biotônico Fontoura and Zero-Cal.
Through the Neo Química brand, the Company is the leader in the markets that it operates for similars/generic medicines, with presence in 96% of Brazilian pharmaceutical points of sale, according to IQVIA, consistent with its mission to provide access to health for the Brazilian population.
In 2021, Hypera Pharma also started to operate in the Non-Retail Market, which includes the Public Health System, as well as private clinics and hospitals. The team has experienced professionals, and the Company has already mapped out an innovation pipeline for the launch of more than 94 molecules over the next few years in Oncology, Specialty Care and Biologicals, in addition to its operations through the joint-venture Bionovis.
The strength of the Company in the pharmaceutical market is supported by a large-scale and low-cost operation based in the largest pharmaceutical operating complex in Latin America, located in Anápolis, Goiás. It is a 120,000-square meter structure with more than 9,000 employees. Annually it produces more than 650 million solid doses, 20 million units of injectable drugs and eye drops, more than 250 million units of vitamins and 300 million units of liquids, creams, oils and lotions.
To support constant innovation in its business, the Company created in 2017 Hynova, the most modern pharmaceutical research center in Brazil, which houses a team of highly qualified professionals, masters and doctors for the development of medicines, dermocosmetics and nutraceuticals, using cutting-edge technology to be a pioneer in Brazil.
The Company also has a broad national sales and distribution structure. Its products are distributed throughout Brazil, directly to retailers, or indirectly through distributors and wholesalers.
Founded in 2001 as Hypermarcas, its corporate name changed in 2017 to Hypera Pharma, evidencing the Company’s new focus in the pharmaceutical market. It is listed in B3’s Novo Mercado since 2008 and currently employs around 10,000 people.
The Company started to operate in December, 2001, and for more than a decade it was one of the leading companies in the consumer goods market in Brazil, participating in the markets of Personal Care, Cleaning and Food until 2006. In 2007, the Company also entered the pharmaceutical market by acquiring DM Indústria Farmacêutica, having subsequently consolidated its position among the leading companies in this sector in Brazil with the acquisitions of Farmasa, in 2008, Neo Química, in 2009 and Mantecorp, in 2011.
In 2012, along with other three Brazilian industries the Company formed the joint venture BIONOVIS S.A. – the Brazilian Biotech Phamarceutical Company, which is focused on the biotechnology products segment.
In order to focus exclusively on the Brazilian pharmaceutical market, in 2015, the Company started a new cycle in its strategic planning, selling its Cosmetics operation to Coty, and then its Condom operation to Reckitt Benckiser Brasil in 2016 and the Disposables business for Ontex, whose transaction was completed in 2017.
In 2020, the Company completed the acquisition of the “Buscopan” and “Buscofem” family of products from Boehringer Ingelheim. The brands Buscopan and Buscofem represent the second largest brand franchise in the OTC market in Brazil.
Also in 2020, the Company invested in Simple Organic Beauty, the first investment of Hypera Ventures, its corporate venture capital initiative that seeks to invest in startups linked to the health and well-being sector and that have synergy with its businesses. Simple Organic Beauty is a digital native startup that operates in the dermocosmetics and makeup markets, leveraging the beauty industry’s high technology to formulate pioneering products in the Clean Beauty industry.
In 2021, the Company completed the acquisition of a selected portfolio from Takeda, including the brands Neosaldina, the third largest franchise in OTC market in Brazil, Dramin and Nebacetin, in addition to the patented brands Nesina and Alektos.
Also in 2021, the Company launched the ihypera e-commerce platform (www.ihypera.com.br), with the purpose of getting even closer to its end consumers to understand their consumption habits and boost sales and promote quality health to the Brazilian population.
Finally, in 2021, the Company celebrated the acquisition of Bioage and, with that, the entry into the Beauticians market in order to strengthen its presence in the Brazilian Skincare market through innovative products and brands, which are complementary to its current businesses. Bioage has a D2C platform and 55 regional franchisees to boost its sales and contribute to the loyalty of skin health and wellness professionals in Brazil.
In 2022, the Company concluded the acquisition of a portfolio of over-the-counter and prescription drugs from Sanofi, including the analgesic AAS, the phytotherapic Naturetti and the antiseptic Cepacol, in addition to the prescription drugs Buclina, for appetite stimulation, and Hidantal, indicated for the treatment of epilepsy, among others.
Also in 2022, an agreement was signed with Boehringer Ingelheim to acquire the company responsible for the production and know-how of raw material related to scopolamine, the active ingredient of the drug Buscopan, ensuring autonomy in the supply of the main input and allowing the sale of exceeding raw material to third parties.
Finally, in June 2022, the Company entered into the Establishment Purchase Agreement with Boehringer Ingelheim, aiming at the acquisition of the manufacturing plant located in Itapecerica da Serra (SP) and responsible for the Buscopan family medicines production.